A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-07. Anything still debated is marked as such rather than presented as settled.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Autoimmune estrogen dermatitis Autoimmune progesterone dermatitis Autosensitization dermatitis Breast eczema (nipple eczema) Chronic vesiculobullous hand eczema Circumostomy eczema Dyshidrosis (acute vesiculobullous hand eczema, cheiropompholyx, dyshidrotic eczema, pompholyx, podopompholyx) Ear eczema Eyelid dermatitis Hand eczema Hyperkeratotic hand dermatitis Id reaction (disseminated eczema, generalized eczema) Irritant diaper dermatitis (diaper dermatitis, napkin dermatitis) Juvenile plantar dermatosis (atopic winter feet, dermatitis plantaris sicca, forefoot dermatitis, moon-boot foot syndrome, sweaty sock dermatitis) Molluscum dermatitis Nummular dermatitis (discoid eczema, microbial eczema, nummular eczema, nummular neurodermatitis) Nutritional deficiency eczema Sulzberger–Garbe syndrome (oid-oid disease) Xerotic eczema (asteatotic eczema, desiccation dermatitis, eczema craquelé, pruritus hiemalis, winter eczema, winter itch)
=== Fibers === In the laboratory, home, or art studio, the acid used in the dye-bath is often vinegar (acetic acid) or citric acid. The uptake rate of the dye is controlled with the use of sodium chloride. In textiles, acid dyes are effective on protein fibers, i.e. animal hair fibers like wool, alpaca, and mohair. They are also effective on silk. They are effective in dyeing the synthetic fiber nylon, but of minimum interest in dyeing any other synthetic fibers.
== Statement on the Islamic State Offensive in the Middle East (2014) == In August 2014 in the daily newspaper Berliner Zeitung, Kermani called for the Islamic State (IS) in Iraq to be stopped, even by military means. He compared the conflict’s significance to that of World War I and warned of a genocide against Christians, Yazidis, and other religious minorities. In his statement, he emphasized the importance of humanitarian corridors for refugees and warned of a Pol Pot-style version of Islam stretching from the borders of Iran to the Mediterranean coast. In his Peace Prize acceptance speech in October 2015, Kermani called for action against the Islamic State, action that would have to be taken militarily, if necessary, but, above all, through diplomacy and civil society, however, much more resolutely than before. While saying that he was not calling for war, he pointed out that the war could no longer be ended in Syria and Iraq alone. It could only be ended by the powers behind the opposing armies and militias: Iran, Turkey, the Gulf states, Russia, and also the West.
Sources: en.wikipedia.org
In a clinical trial, the rate of systolic orthostatic hypotension was 21% versus 9% with placebo and the rate of diastolic orthostatic hypotension was 12% versus 4% with placebo in people with Parkinson's disease taking the ODT form of selegiline. The risk of hypotension is greater at the start of treatment and in the elderly (3% vs. 0% with placebo). The rate of hypotension or orthostatic hypotension with the selegiline patch was 2.2% versus 0.5% with placebo in clinical trials of people with depression. Significant orthostatic blood pressure changes (≥10 mm Hg decrease) occurred in 9.8% versus 6.7% with placebo, but most of these cases were asymptomatic and heart rate was unchanged. The rates of other orthostatic hypotension-related side effects in this population were dizziness or vertigo 4.9% versus 3.1% with placebo and fainting 0.5% versus 0.0% with placebo. It is said that orthostatic hypotension is rarely seen with the selegiline transdermal patch compared to oral MAOIs. Caution is advised against rapidly rising after sitting or lying, especially after prolonged periods or at the start of treatment, as this can result in fainting. Falls are of particular concern in the elderly. MAOIs like selegiline may lower blood pressure by increasing dopamine levels and activating dopamine receptors, by increasing levels of the false neurotransmitter octopamine, and/or by other mechanisms. Meta-analyses published in the 1990s found that the addition of selegiline to levodopa increased mortality in people with Parkinson's disease.
Hazard research is published: several dietary habits and products including teabags are linked to PFAS intake (4 Feb), an additional three billion people may face water scarcity by 2050 when river pollution is considered, an aspect neglected by prior assessments (6 Feb), HPV infection linked to higher cardiovascular mortality (7 Feb), researchers use simulations to develop an early-warning signal for a potential collapse of the atlantic meridional overturning circulation (AMOC) and suggest it indicates the AMOC is "on route to tipping" (9 Feb), researchers report the H5N1 bird flu virus may be changing and adapting to infect more mammals (12 Feb), researchers report how compounding disturbances could trigger unexpected ecosystem transitions in the Amazon rainforest (14 Feb), harmful chlormequat is found in ~80% of U.S. adult urine samples, rising during 2023, and in oat-based foods widely thought to be healthy (15 Feb), excess amounts of widely-supplemented niacin (B3) are linked to cardiovascular risk (19 Feb), a review concludes available evidence on the use of puberty blockers and cross-sex hormones in minors with gender dysphoria is very limited and based on only a few studies with small numbers which have problematic methodology and quality, warning about their use outside of clinical studies or research projects after careful risk-benefit evaluation (27 Feb).
Many catabolic biochemical processes, such as glycolysis, the citric acid cycle, and beta oxidation, produce the reduced coenzyme NADH. This coenzyme contains electrons that have a high transfer potential; in other words, they will release a large amount of energy upon oxidation. However, the cell does not release this energy all at once, as this would be an uncontrollable reaction. Instead, the electrons are removed from NADH and passed to oxygen through a series of enzymes that each release a small amount of the energy. This set of enzymes, consisting of complexes I through IV, is called the electron transport chain and is found in the inner membrane of the mitochondrion. In eukaryotes, the enzymes in this electron transport system use the energy released from O2 by NADH to pump protons across the inner membrane of the mitochondrion. This causes protons to build up in the intermembrane space, and generates an electrochemical gradient across the membrane. The energy stored in this potential is then used by ATP synthase to produce ATP. Oxidative phosphorylation in the eukaryotic mitochondrion is the best-understood example of this process. The mitochondrion is present in almost all eukaryotes, with the exception of anaerobic protozoa such as Trichomonas vaginalis that instead reduce protons to hydrogen in a remnant mitochondrion called a hydrogenosome.
Sources: en.wikipedia.org
== Reactions == Foreign Policy magazine stated that a poll of Latin Americans living across the Americas, including the US and Canada, in October 2025 showed "fairly strong levels of support among people in the region for a US military intervention in Venezuela to depose Maduro and his government", adding that people in Latin America were more "likely to support such a scenario" than US respondents.
=== Bombing test === This method applies to objects that are supposedly hermetically sealed such as implantable medical devices, crystal oscillator, saw filter devices, transistors, microprocessors, etc. First the device under test will be exposed to helium pressure (typically 30-60psi) in a "bombing" chamber for an extended time period. If the part is leaky, helium will be able to penetrate the device. Later the device will be placed in a vacuum chamber, connected to a vacuum pump and a mass spectrometer. The tiny amount of gas that entered the device under pressure will be released in the vacuum chamber and sent to the mass spectrometer where the leak rate will be measured down to 10−9 mbar·L·s−1. This method is not able to detect a massive leak as the tracer gas will be quickly pumped out when test chamber is pumped down.
== End-of-use == Plastic: Landfilling, burning, and recycling are all alternatives for plastic packaging at the end of their shelf-life. However, improper disposal and handling lead to higher percentages of plastic waste, which can pollute the environment in a wide spectrum of scenarios. The packaging sector accounts for 40.5% of all plastic produced in Europe, which represents the largest sector in food industry. However, the recycling of such wastege is at a critical low level of roughly 35%. Moreover, it has been estimated that over 20% of the plastic packaging does not reach any recycling process. Bioplastic: also known as biodegradable polymer or biopolymer, are usually made from renewable feedstock resources like corn, potatoes, wood pulp and sugarcane, as well as from renewable natural resources of different kind. Typical end-of-life options include the composting or the environmental degradation of bioplastics, which result in resource loss and CO2 production. Complete degradation is also only achievable under rigorous conditions that are infrequently offered by the company. Additionally, some bioplastics are processed similarly to their traditional, fossil-based counterparts, which, if improperly sorted, might cause harmful interferences in other materials' recycling processes. Paper, paperboard, and corrugated board: are composed of cellulosic fibers bonded together to form a flexible structure.
India Archived 11 January 2021 at the Wayback Machine. The World Factbook. Central Intelligence Agency. India web resources provided by GovPubs at the University of Colorado Boulder Libraries India from BBC News Wikimedia Atlas of India Geographic data related to India at OpenStreetMap Key Development Forecasts for India from International Futures
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.